{"id":"W3217494531","doi":"10.1016/s1470-2045(21)00578-7","title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":353,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto; University Health Network","funders":"National Cancer Institute; Loxo Oncology; PharmaMar; Innovent Biologics; Incyte; Sanofi; Andrew Sabin Family Foundation; National Institutes of Health; Helsinn; GlaxoSmithKline; University of Texas MD Anderson Cancer Center; Pfizer; Novartis Pharmaceuticals Corporation; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Dabrafenib; Trametinib; Glioma; Glioblastoma; Temozolomide; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004139132,0.0003349292,0.001281089,0.0001236395,0.0001216294,0.00008538438,0.0002801733,0.0001922747,0.0001770364],"category_scores_gemma":[0.0002654841,0.0002082354,0.00005078514,0.0005124994,0.0002191885,0.0001077315,0.0002236623,0.0003644765,0.00001663022],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003952492,"about_ca_system_score_gemma":0.0003448902,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00019481,"about_ca_topic_score_gemma":0.0006492002,"domain_scores_codex":[0.9973403,0.0005402308,0.0005089027,0.0006209196,0.0003324287,0.0006572072],"domain_scores_gemma":[0.9981026,0.0006873906,0.0002425415,0.0006344827,0.000105709,0.0002272638],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4632455,0.3245948,0.06432095,0.0004460315,0.002578277,0.01709221,0.005702504,0.00005642036,0.02790993,0.002609937,0.009235332,0.08220812],"study_design_scores_gemma":[0.9328076,0.01602377,0.02883385,0.0002760213,0.0006577907,0.0001737379,0.0003403026,0.0003160138,0.01132996,0.0001832999,0.008690294,0.0003673243],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9845632,0.0004291302,0.000005812216,0.01156509,0.0004015364,0.002435576,0.0001083572,0.00004714894,0.000444178],"genre_scores_gemma":[0.9957567,0.0001051377,0.001474345,0.001775103,0.0003232129,0.0002730056,0.0002070739,0.00004464596,0.00004070175],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4695622,"threshold_uncertainty_score":0.8491594,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06301962313348018,"score_gpt":0.3484888677724673,"score_spread":0.2854692446389872,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}